Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are rising in Thursday's after-hours session following the company's first-quarter financial results.
Recursion Pharmicals Inc（納斯達克股票代碼：RXRX）公佈第一季度財務業績後，該公司股價在週四盤後交易中上漲。
Q1 Earnings: Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share, which beat estimates for a loss of 42 cents per share.
第一季度收益：根據Benzinga Pro的數據，Recursion公佈的第一季度收入爲1349.1萬美元，超過了分析師預期的1,265萬美元。該公司報告每股季度虧損39美分，超過預期的每股虧損42美分。
Net cash used in operating activities was $102.3 million in the first quarter. The company ended the quarter with $296.3 million in cash and cash equivalents.
第一季度用於經營活動的淨現金爲1.023億美元。該公司在本季度末擁有2.963億美元的現金及現金等價物。
Recursion said it's on track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in the third quarter.
Recursion表示，從第三季度開始，它有望在未來幾個季度公佈多項2期臨床試驗。
"We are excited about the multiple upcoming value catalysts that could potentially occur in the near-term, including clinical trial readouts, partnership option exercises, new partnerships, and interest in Recursion's data and technology solutions," said Chris Gibson, co-founder and CEO of Recursion.
Recursion聯合創始人兼首席執行官克里斯·吉布森表示：“我們對短期內可能出現的多種即將到來的價值催化劑感到興奮，包括臨床試驗報告、夥伴關係期權行使、新的合作伙伴關係以及對Recursion數據和技術解決方案的興趣。”
"It is great to see individuals from both the biopharma and technology industries demonstrating an understanding and appetite for the power of combining large-scale computing resources with the ability to generate a proprietary source of large-scale data."
“很高興看到來自生物製藥和技術行業的個人對將大規模計算資源與生成專有大規模數據源的能力相結合的力量表現出理解和興趣。”
Recursion highlighted supercomputer expansion in the first quarter in partnership with Nvidia Corp (NASDAQ:NVDA). The company said it's working with the chipmaker to design and build BioHive-2, its next-generation supercomputer with over 500 H100 GPUs.
Recursion強調了與英偉達公司（納斯達克股票代碼：NVDA）合作在第一季度進行的超級計算機擴張。該公司表示，正在與芯片製造商合作設計和製造BioHive-2，這是其下一代超級計算機，擁有超過500個H100 GPU。
"We have nearly completed the build-out of BioHive-2 and began performance benchmarking tests. We believe that the performance of our supercomputer may place BioHive-2 in the top 50 of the next TOP500 list, making it one of the most powerful supercomputers in the world across any industry and the most powerful supercomputer owned and operated by any biopharma company," the company said.
“我們幾乎已經完成了BioHive-2的構建，並開始了性能基準測試。我們認爲，我們的超級計算機的性能可能會使BioHive-2進入下一個TOP500 榜單的前50名，使其成爲世界上所有行業中最強大的超級計算機之一，也是所有生物製藥公司擁有和運營的最強大的超級計算機，” 該公司表示。
Nvidia reported investments in multiple companies in a 13-F filing with the SEC earlier this year. Recursion Pharmaceuticals was among the names listed. According to the filing, the company is Nvidia's second-largest investment after Arm Holdings.
英偉達在今年早些時候向美國證券交易委員會提交的13-F文件中報告了對多家公司的投資。Recursion Pharmaceuticals就是其中之一。根據該文件，該公司是英偉達僅次於Arm Holdings的第二大投資。
RXRX Price Action: Recursion shares were up 0.58% at $8.64 after-hours Thursday, according to Benzinga Pro.
RXRX價格走勢：根據Benzinga Pro的數據，Recursion股價週四盤後上漲0.58％，至8.64美元。
Don't Miss: SoundHound AI Q1 Earnings: Revenue Beat, EPS Beat, 'Business Momentum Continues To Accelerate' And More
千萬不要錯過：SoundHound AI 第一季度收益：收入超過預期、每股收益超過預期、“業務勢頭持續加速” 等
Photo: Shutterstock.
照片：Shutterstock。
譯文內容由第三人軟體翻譯。